|First Patient Cohort Data From BioTime’s OpRegen® Clinical Trial in Dry-AMD to Be Presented at ISOPT Clinical Symposium on December 2, 2016|
October 20, 2016
|- OpRegen at the first dose caused no serious adverse events in the
first patient cohort -
- Retinal imaging suggests presence and survival of the transplanted
cells in the subretinal space for up to one year -
ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 20, 2016--
BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical stage biotechnology
company with a focus on pluripotent stem cell technologies, today
reported that data from the first patient... |
|LifeMap Solutions Joins Medidata AppConnect Partner Program to Drive mHealth Innovation|
October 18, 2016
|LifeMap Solutions to participate in annual Medidata Symposium,
showcasing demo app that studies the effects of caffeine consumption
SAN JOSE, Calif.--(BUSINESS WIRE)--Oct. 18, 2016--
LifeMap Solutions, the digital health subsidiary of BioTime, Inc. (NYSE
MKT: BTX), today announced a partnership with Medidata (NASDAQ: MDSO),
the leading provider of cloud-based solutions for clinical research.
LifeMap is joining Medidata’s AppConn... |
|BioTime to Present at the BIO Investor Forum|
October 13, 2016
|ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 13, 2016--
BioTime, Inc. (NYSE MKT: BTX), a clinical stage biotechnology company
with a focus on pluripotent stem cell technology, today announced that
Adi Mohanty, Co-Chief Executive Officer, will be presenting at the BIO
Investor Forum on Wednesday, October 19, 2016, at 2:00 p.m. Pacific Time
/ 5:00 p.m. Eastern Time. The BIO Investor Forum is being held at the
Westin St. Francis Hotel in San Francisco.
View Committee Composition
Find the latest financial information
DISCLAIMER: You are about to review presentations, reports, filings and/or other materials regarding BioTime, Inc. (NYSE: MKT and TASE: BTX) that contain time-sensitive information. The information contained therein is only current as of the date thereof. BioTime expressly disclaims any obligation to review, update or correct these materials after the date thereof. BioTime may update, amend, supplement or otherwise alter the information contained in any such materials by subsequent presentations, reports, filings, or other means without notice.
Certain statements made on this website or in materials accessed in or through this section of our website are "forward-looking statements," which are subject to risks and uncertainties, and BioTime's actual results may differ (possibly materially) from those indicated in such statements.
|Data provided by Nasdaq. Minimum 15 minutes delayed.|